Lenalidomide Cf

Lenalidomide, the active ingredient in Lenalidomide Cf, is an immunomodulatory drug presented as an oral tablet (strength not specified) for oral use. It is used in the treatment of multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from comprehensive regulatory support and timely delivery across multiple regions.

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders, targeting disease pathways that drive abnormal cell growth.

- Multiple myeloma: improves progression‑free and overall survival in eligible patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may improve blood counts. - Relapsed or refractory disease: offers a therapeutic option after prior therapies have failed.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: skin irritation or erythema. - Nausea: upset stomach, sometimes with vomiting. - Cytopenias: reduced white blood cells, red blood cells, or platelets. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe infections: opportunistic or bacterial infections requiring prompt treatment. - Secondary malignancies: emergence of new cancers during therapy. - Hepatotoxicity: significant liver enzyme elevations. - Cardiac arrhythmias: irregular heart rhythms in susceptible patients.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor laboratory parameters regularly.

- Pregnancy risk: avoid use in pregnant women; teratogenic potential requires effective contraception. - Renal function: adjust monitoring for patients with impaired kidney function. - Hepatic function: assess liver enzymes before and during treatment. - Thrombotic risk: consider prophylactic anticoagulation in high‑risk individuals. - Infection vigilance: monitor for signs of infection and treat promptly. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants: increased risk of bleeding when combined with lenalidomide.

Moderate Interactions (Monitor Closely): - Immunosuppressants: heightened infection risk. - NSAIDs: may exacerbate renal toxicity. - Vaccines: live vaccines should be avoided during therapy.